Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 98 entries
Sorted by: Best Match Show Resources per page
Therapeutic drug monitoring of mexiletine at a large academic medical center.

SAGE open medicine

Nei SD, Danelich IM, Lose JM, Leung LY, Asirvatham SJ, McLeod CJ.
PMID: 27708780
SAGE Open Med. 2016 Sep 21;4:2050312116670659. doi: 10.1177/2050312116670659. eCollection 2016.

INTRODUCTION: The therapeutic trough range for mexiletine (0.8-2 mcg/mL) was largely established in the setting of arrhythmia prophylaxis following myocardial infarction.OBJECTIVE: Describe the usage patterns of serum mexiletine concentrations and the impact of these concentrations on mexiletine dosing in...

Cite
Nei SD, Danelich IM, Lose JM, et al. Therapeutic drug monitoring of mexiletine at a large academic medical center. SAGE Open Med. 2016;4:2050312116670659doi: 10.1177/2050312116670659.
Nei, S. D., Danelich, I. M., Lose, J. M., Leung, L. Y., Asirvatham, S. J., & McLeod, C. J. (2016). Therapeutic drug monitoring of mexiletine at a large academic medical center. SAGE open medicine, 42050312116670659. https://doi.org/10.1177/2050312116670659
Nei, Scott D, et al. "Therapeutic drug monitoring of mexiletine at a large academic medical center." SAGE open medicine vol. 4 (2016): 2050312116670659. doi: https://doi.org/10.1177/2050312116670659
Nei SD, Danelich IM, Lose JM, Leung LY, Asirvatham SJ, McLeod CJ. Therapeutic drug monitoring of mexiletine at a large academic medical center. SAGE Open Med. 2016 Sep 21;4:2050312116670659. doi: 10.1177/2050312116670659. eCollection 2016. PMID: 27708780; PMCID: PMC5034464.
Copy Download .nbib Format: NLM
Enhancing hippocampal blood flow after cerebral ischemia and vasodilating basilar arteries: in vivo and in vitro neuroprotective effect of antihypertensive DDPH.

Neural regeneration research

Sun L, Li Q, Wang WT, Chen YH, Guo LJ.
PMID: 26170819
Neural Regen Res. 2015 Apr;10(4):589-93. doi: 10.4103/1673-5374.155432.

1-(2,6-Dimethylphenoxy)-2-(3,4-dimethoxyphenylethylamino)-propane hydrochloride (DDPH) is a novel antihypertensive agent based on structural characteristics of mexiletine and verapamine. We investigated the effect of DDPH on vasodilatation and neuroprotection in a rat model of cerebral ischemia in vivo, and a rabbit model...

Cite
Sun L, Li Q, Wang WT, et al. Enhancing hippocampal blood flow after cerebral ischemia and vasodilating basilar arteries: in vivo and in vitro neuroprotective effect of antihypertensive DDPH. Neural Regen Res. 2015;10(4):589-93doi: 10.4103/1673-5374.155432.
Sun, L., Li, Q., Wang, W. T., Chen, Y. H., & Guo, L. J. (2015). Enhancing hippocampal blood flow after cerebral ischemia and vasodilating basilar arteries: in vivo and in vitro neuroprotective effect of antihypertensive DDPH. Neural regeneration research, 10(4), 589-93. https://doi.org/10.4103/1673-5374.155432
Sun, Li, et al. "Enhancing hippocampal blood flow after cerebral ischemia and vasodilating basilar arteries: in vivo and in vitro neuroprotective effect of antihypertensive DDPH." Neural regeneration research vol. 10,4 (2015): 589-93. doi: https://doi.org/10.4103/1673-5374.155432
Sun L, Li Q, Wang WT, Chen YH, Guo LJ. Enhancing hippocampal blood flow after cerebral ischemia and vasodilating basilar arteries: in vivo and in vitro neuroprotective effect of antihypertensive DDPH. Neural Regen Res. 2015 Apr;10(4):589-93. doi: 10.4103/1673-5374.155432. PMID: 26170819; PMCID: PMC4424751.
Copy Download .nbib Format: NLM
New classification and treatment for myotonic disorders.

Internal medicine (Tokyo, Japan)

Kurihara T.
PMID: 16293911
Intern Med. 2005 Oct;44(10):1027-32. doi: 10.2169/internalmedicine.44.1027.

Myotonia is repetitive firing of muscle action potentials causing prolonged muscle contractions even after mechanical stimulations to the muscles have ceased. Most common myotonic disorder is myotonic dystrophy which is now termed DM1, myotonic dystrophy type 1. In Japan,...

Cite
Kurihara T. New classification and treatment for myotonic disorders. Intern Med. 2005;44(10):1027-32doi: 10.2169/internalmedicine.44.1027.
Kurihara, T. (2005). New classification and treatment for myotonic disorders. Internal medicine (Tokyo, Japan), 44(10), 1027-32. https://doi.org/10.2169/internalmedicine.44.1027
Kurihara, Teruyuki. "New classification and treatment for myotonic disorders." Internal medicine (Tokyo, Japan) vol. 44,10 (2005): 1027-32. doi: https://doi.org/10.2169/internalmedicine.44.1027
Kurihara T. New classification and treatment for myotonic disorders. Intern Med. 2005 Oct;44(10):1027-32. doi: 10.2169/internalmedicine.44.1027. PMID: 16293911.
Copy Download .nbib Format: NLM
Pharmacologic management of chronic pain.

The Korean journal of pain

Park HJ, Moon DE.
PMID: 20556211
Korean J Pain. 2010 Jun;23(2):99-108. doi: 10.3344/kjp.2010.23.2.99. Epub 2010 May 31.

Chronic pain is a multifactorial condition with both physical and psychological symptoms, and it affects around 20% of the population in the developed world. In spite of outstanding advances in pain management over the past decades, chronic pain remains...

Cite
Park HJ, Moon DE. Pharmacologic management of chronic pain. Korean J Pain. 2010;23(2):99-108doi: 10.3344/kjp.2010.23.2.99.
Park, H. J., & Moon, D. E. (2010). Pharmacologic management of chronic pain. The Korean journal of pain, 23(2), 99-108. https://doi.org/10.3344/kjp.2010.23.2.99
Park, Hue Jung, and Moon, Dong Eon. "Pharmacologic management of chronic pain." The Korean journal of pain vol. 23,2 (2010): 99-108. doi: https://doi.org/10.3344/kjp.2010.23.2.99
Park HJ, Moon DE. Pharmacologic management of chronic pain. Korean J Pain. 2010 Jun;23(2):99-108. doi: 10.3344/kjp.2010.23.2.99. Epub 2010 May 31. PMID: 20556211; PMCID: PMC2886242.
Copy Download .nbib Format: NLM
The influence of urinary pH on the elimination of mexiletine.

British journal of clinical pharmacology

Kiddie MA, Kaye CM, Turner P, Shaw TR.
PMID: 22454952
Br J Clin Pharmacol. 1974 Jun;1(3):229-32. doi: 10.1111/j.1365-2125.1974.tb00241.x.

1 The plasma elimination half-life of mexiletine was measured in four subjects when the urine was rendered (a) acidic and (b) alkaline. 2 Urinary acidification (pH 5.0) was associated with a plasma elimination half-life of 2.8 h and 57.5%...

Cite
Kiddie MA, Kaye CM, Turner P, et al. The influence of urinary pH on the elimination of mexiletine. Br J Clin Pharmacol. 1974;1(3):229-32doi: 10.1111/j.1365-2125.1974.tb00241.x.
Kiddie, M. A., Kaye, C. M., Turner, P., & Shaw, T. R. (1974). The influence of urinary pH on the elimination of mexiletine. British journal of clinical pharmacology, 1(3), 229-32. https://doi.org/10.1111/j.1365-2125.1974.tb00241.x
Kiddie, M A, et al. "The influence of urinary pH on the elimination of mexiletine." British journal of clinical pharmacology vol. 1,3 (1974): 229-32. doi: https://doi.org/10.1111/j.1365-2125.1974.tb00241.x
Kiddie MA, Kaye CM, Turner P, Shaw TR. The influence of urinary pH on the elimination of mexiletine. Br J Clin Pharmacol. 1974 Jun;1(3):229-32. doi: 10.1111/j.1365-2125.1974.tb00241.x. PMID: 22454952; PMCID: PMC1402565.
Copy Download .nbib Format: NLM
The renal excretion of mexiletine (Kö 1173) under controlled conditions of urine pH.

British journal of clinical pharmacology

Kiddie MA, Kaye CM.
PMID: 22454877
Br J Clin Pharmacol. 1974 Feb;1(1):86-7. doi: 10.1111/j.1365-2125.1974.tb00214.x.

No abstract available.

Cite
Kiddie MA, Kaye CM. The renal excretion of mexiletine (Kö 1173) under controlled conditions of urine pH. Br J Clin Pharmacol. 1974;1(1):86-7doi: 10.1111/j.1365-2125.1974.tb00214.x.
Kiddie, M. A., & Kaye, C. M. (1974). The renal excretion of mexiletine (Kö 1173) under controlled conditions of urine pH. British journal of clinical pharmacology, 1(1), 86-7. https://doi.org/10.1111/j.1365-2125.1974.tb00214.x
Kiddie, M A, and Kaye, C M. "The renal excretion of mexiletine (Kö 1173) under controlled conditions of urine pH." British journal of clinical pharmacology vol. 1,1 (1974): 86-7. doi: https://doi.org/10.1111/j.1365-2125.1974.tb00214.x
Kiddie MA, Kaye CM. The renal excretion of mexiletine (Kö 1173) under controlled conditions of urine pH. Br J Clin Pharmacol. 1974 Feb;1(1):86-7. doi: 10.1111/j.1365-2125.1974.tb00214.x. PMID: 22454877; PMCID: PMC1402406.
Copy Download .nbib Format: NLM
Electrophysiological characterization of drug response in hSC-derived cardiomyocytes using voltage-sensitive optical platforms.

Journal of pharmacological and toxicological methods

Pfeiffer-Kaushik ER, Smith GL, Cai B, Dempsey GT, Hortigon-Vinagre MP, Zamora V, Feng S, Ingermanson R, Zhu R, Hariharan V, Nguyen C, Pierson J, Gintant GA, Tung L.
PMID: 31319140
J Pharmacol Toxicol Methods. 2019 Sep - Oct;99:106612. doi: 10.1016/j.vascn.2019.106612. Epub 2019 Jul 15.

INTRODUCTION: Voltage-sensitive optical (VSO) sensors offer a minimally invasive method to study the time course of repolarization of the cardiac action potential (AP). This Comprehensive in vitro Proarrhythmia Assay (CiPA) cross-platform study investigates protocol design and measurement variability of...

Cite
Pfeiffer-Kaushik ER, Smith GL, Cai B, et al. Electrophysiological characterization of drug response in hSC-derived cardiomyocytes using voltage-sensitive optical platforms. J Pharmacol Toxicol Methods. 2019;99:106612doi: 10.1016/j.vascn.2019.106612.
Pfeiffer-Kaushik, E. R., Smith, G. L., Cai, B., Dempsey, G. T., Hortigon-Vinagre, M. P., Zamora, V., Feng, S., Ingermanson, R., Zhu, R., Hariharan, V., Nguyen, C., Pierson, J., Gintant, G. A., & Tung, L. (2019). Electrophysiological characterization of drug response in hSC-derived cardiomyocytes using voltage-sensitive optical platforms. Journal of pharmacological and toxicological methods, 99106612. https://doi.org/10.1016/j.vascn.2019.106612
Pfeiffer-Kaushik, Emily R, et al. "Electrophysiological characterization of drug response in hSC-derived cardiomyocytes using voltage-sensitive optical platforms." Journal of pharmacological and toxicological methods vol. 99 (2019): 106612. doi: https://doi.org/10.1016/j.vascn.2019.106612
Pfeiffer-Kaushik ER, Smith GL, Cai B, Dempsey GT, Hortigon-Vinagre MP, Zamora V, Feng S, Ingermanson R, Zhu R, Hariharan V, Nguyen C, Pierson J, Gintant GA, Tung L. Electrophysiological characterization of drug response in hSC-derived cardiomyocytes using voltage-sensitive optical platforms. J Pharmacol Toxicol Methods. 2019 Sep - Oct;99:106612. doi: 10.1016/j.vascn.2019.106612. Epub 2019 Jul 15. PMID: 31319140.
Copy Download .nbib Format: NLM
Calixmexitil: Calixarene-based Cluster of Mexiletine with Amplified Anti-myotonic Activity as A Novel Use-dependent Sodium Channel Blocker.

Iranian journal of pharmaceutical research : IJPR

Delnavaz Shahr A, Nasuhi Pur F.
PMID: 32641945
Iran J Pharm Res. 2019;18(3):1351-1357. doi: 10.22037/ijpr.2019.1100768.

Mexiletine as the first choice drug in myotonia treatment is a chiral sodium channel blocker clinically used in its racemic form. The phenolic structure of this drug, prompted us to design its novel calix[4]arene-based cluster in a chalice-shaped structure....

Cite
Delnavaz Shahr A, Nasuhi Pur F. Calixmexitil: Calixarene-based Cluster of Mexiletine with Amplified Anti-myotonic Activity as A Novel Use-dependent Sodium Channel Blocker. Iran J Pharm Res. 2019;18(3):1351-1357doi: 10.22037/ijpr.2019.1100768.
Delnavaz Shahr, A., & Nasuhi Pur, F. (2019). Calixmexitil: Calixarene-based Cluster of Mexiletine with Amplified Anti-myotonic Activity as A Novel Use-dependent Sodium Channel Blocker. Iranian journal of pharmaceutical research : IJPR, 18(3), 1351-1357. https://doi.org/10.22037/ijpr.2019.1100768
Delnavaz Shahr, Amirali, and Nasuhi Pur, Fazel. "Calixmexitil: Calixarene-based Cluster of Mexiletine with Amplified Anti-myotonic Activity as A Novel Use-dependent Sodium Channel Blocker." Iranian journal of pharmaceutical research : IJPR vol. 18,3 (2019): 1351-1357. doi: https://doi.org/10.22037/ijpr.2019.1100768
Delnavaz Shahr A, Nasuhi Pur F. Calixmexitil: Calixarene-based Cluster of Mexiletine with Amplified Anti-myotonic Activity as A Novel Use-dependent Sodium Channel Blocker. Iran J Pharm Res. 2019;18(3):1351-1357. doi: 10.22037/ijpr.2019.1100768. PMID: 32641945; PMCID: PMC6934949.
Copy Download .nbib Format: NLM
Evaluation of the antinociceptive activities of several sodium channel blockers using veratrine test in mice.

Synapse (New York, N.Y.)

Yoshizawa K, Arai N, Suzuki Y, Nakamura T, Takeuchi K, Sakamoto R, Masuda R.
PMID: 29993143
Synapse. 2018 Jul 11; doi: 10.1002/syn.22056. Epub 2018 Jul 11.

An important role of voltage-gated sodium channels (VGSCs) in many different pain states has been established in animal models and humans wherein sodium channel blockers partially ameliorate pain. However, behavioral tests for screening analgesics that exhibit pharmacologic action by...

Cite
Yoshizawa K, Arai N, Suzuki Y, et al. Evaluation of the antinociceptive activities of several sodium channel blockers using veratrine test in mice. Synapse. 2018;doi: 10.1002/syn.22056.
Yoshizawa, K., Arai, N., Suzuki, Y., Nakamura, T., Takeuchi, K., Sakamoto, R., & Masuda, R. (2018). Evaluation of the antinociceptive activities of several sodium channel blockers using veratrine test in mice. Synapse (New York, N.Y.), . https://doi.org/10.1002/syn.22056
Yoshizawa, Kazumi, et al. "Evaluation of the antinociceptive activities of several sodium channel blockers using veratrine test in mice." Synapse (New York, N.Y.) vol. (2018). doi: https://doi.org/10.1002/syn.22056
Yoshizawa K, Arai N, Suzuki Y, Nakamura T, Takeuchi K, Sakamoto R, Masuda R. Evaluation of the antinociceptive activities of several sodium channel blockers using veratrine test in mice. Synapse. 2018 Jul 11; doi: 10.1002/syn.22056. Epub 2018 Jul 11. PMID: 29993143.
Copy Download .nbib Format: NLM
Co-occurrence of DMPK expansion and CLCN1 mutation in a patient with myotonia.

Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology

Locci S, Cardani R, Brunori P, Lucchiari S, Comi GP, Federico A, De Stefano N, Meola G, Mignarri A.
PMID: 34386887
Neurol Sci. 2021 Dec;42(12):5365-5368. doi: 10.1007/s10072-021-05538-y. Epub 2021 Aug 13.

INTRODUCTION: Myotonic disorders are a group of diseases affecting the muscle, in different ways. Myotonic dystrophy type 1 (DM1) is related to (CTG)n expansion in the 3-untranslated region of the dystrophia myotonica protein kinase (DMPK) gene and is the...

Cite
Locci S, Cardani R, Brunori P, et al. Co-occurrence of DMPK expansion and CLCN1 mutation in a patient with myotonia. Neurol Sci. 2021;42(12):5365-5368doi: 10.1007/s10072-021-05538-y.
Locci, S., Cardani, R., Brunori, P., Lucchiari, S., Comi, G. P., Federico, A., De Stefano, N., Meola, G., & Mignarri, A. (2021). Co-occurrence of DMPK expansion and CLCN1 mutation in a patient with myotonia. Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 42(12), 5365-5368. https://doi.org/10.1007/s10072-021-05538-y
Locci, Sara, et al. "Co-occurrence of DMPK expansion and CLCN1 mutation in a patient with myotonia." Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology vol. 42,12 (2021): 5365-5368. doi: https://doi.org/10.1007/s10072-021-05538-y
Locci S, Cardani R, Brunori P, Lucchiari S, Comi GP, Federico A, De Stefano N, Meola G, Mignarri A. Co-occurrence of DMPK expansion and CLCN1 mutation in a patient with myotonia. Neurol Sci. 2021 Dec;42(12):5365-5368. doi: 10.1007/s10072-021-05538-y. Epub 2021 Aug 13. PMID: 34386887.
Copy Download .nbib Format: NLM
Expression defect of the rare variant/Brugada mutation R1512W depends upon the SCN5A splice variant background and can be rescued by mexiletine and the common polymorphism H558R.

Channels (Austin, Tex.)

Hu RM, Song EJ, Tester DJ, Deschenes I, Ackerman MJ, Makielski JC, Tan BH.
PMID: 33535892
Channels (Austin). 2021 Dec;15(1):253-261. doi: 10.1080/19336950.2021.1875645.

No abstract available.

Cite
Hu RM, Song EJ, Tester DJ, et al. Expression defect of the rare variant/Brugada mutation R1512W depends upon the SCN5A splice variant background and can be rescued by mexiletine and the common polymorphism H558R. Channels (Austin). 2021;15(1):253-261doi: 10.1080/19336950.2021.1875645.
Hu, R. M., Song, E. J., Tester, D. J., Deschenes, I., Ackerman, M. J., Makielski, J. C., & Tan, B. H. (2021). Expression defect of the rare variant/Brugada mutation R1512W depends upon the SCN5A splice variant background and can be rescued by mexiletine and the common polymorphism H558R. Channels (Austin, Tex.), 15(1), 253-261. https://doi.org/10.1080/19336950.2021.1875645
Hu, Rou-Mu, et al. "Expression defect of the rare variant/Brugada mutation R1512W depends upon the SCN5A splice variant background and can be rescued by mexiletine and the common polymorphism H558R." Channels (Austin, Tex.) vol. 15,1 (2021): 253-261. doi: https://doi.org/10.1080/19336950.2021.1875645
Hu RM, Song EJ, Tester DJ, Deschenes I, Ackerman MJ, Makielski JC, Tan BH. Expression defect of the rare variant/Brugada mutation R1512W depends upon the SCN5A splice variant background and can be rescued by mexiletine and the common polymorphism H558R. Channels (Austin). 2021 Dec;15(1):253-261. doi: 10.1080/19336950.2021.1875645. PMID: 33535892; PMCID: PMC7872018.
Copy Download .nbib Format: NLM
Peripartum management of patient with long QT3 after successful implantable cardioverter defibrillator device discharge resulting in device failure: a case report.

European heart journal. Case reports

Lee MJ, Monteil DC, Spooner MT.
PMID: 34926986
Eur Heart J Case Rep. 2021 Nov 30;5(12):ytab487. doi: 10.1093/ehjcr/ytab487. eCollection 2021 Dec.

BACKGROUND: Long QT3 syndrome type 3 (LQT3) is a gain of function mutation of the SCN5A gene that is inherited in an autosomal dominant fashion. Long QT3 syndrome type 3 results in an increase in arrhythmic events during rest,...

Cite
Lee MJ, Monteil DC, Spooner MT. Peripartum management of patient with long QT3 after successful implantable cardioverter defibrillator device discharge resulting in device failure: a case report. Eur Heart J Case Rep. 2021;5(12):ytab487doi: 10.1093/ehjcr/ytab487.
Lee, M. J., Monteil, D. C., & Spooner, M. T. (2021). Peripartum management of patient with long QT3 after successful implantable cardioverter defibrillator device discharge resulting in device failure: a case report. European heart journal. Case reports, 5(12), ytab487. https://doi.org/10.1093/ehjcr/ytab487
Lee, Melissa J, et al. "Peripartum management of patient with long QT3 after successful implantable cardioverter defibrillator device discharge resulting in device failure: a case report." European heart journal. Case reports vol. 5,12 (2021): ytab487. doi: https://doi.org/10.1093/ehjcr/ytab487
Lee MJ, Monteil DC, Spooner MT. Peripartum management of patient with long QT3 after successful implantable cardioverter defibrillator device discharge resulting in device failure: a case report. Eur Heart J Case Rep. 2021 Nov 30;5(12):ytab487. doi: 10.1093/ehjcr/ytab487. eCollection 2021 Dec. PMID: 34926986; PMCID: PMC8672658.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 98 entries